HG106 (0-4 mg/kg, once a day, intraperitoneal injection, 26 days) inhibits tumor growth in A549 mouse transplant model[1].
HG106 (0-4 mg/kg, once a day, intraperitoneal injection, 20 days) inhibits tumor growth in mice in a xenograft model and induces apoptosis by triggering endoplasmic membrane stress[1].
| Animal Model: | A549 mouse transplant model[1] |
| Dosage: | 0, 1, 2, 4 mg/kg; daily; 26 days |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth and prolonged the inhibition time of tumor growth. |
| Animal Model: | LUAD patient-derived xenograft (PDX) models harboring the G12V mutation in KRAS[1] |
| Dosage: | 0, 1, 2, 4 mg/kg; daily; 20 days |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth, increased ROS generation and TUNEL signal in patient-derived xenografts validated that HG106 triggered endoplasmic membrane stress-induced apoptosis in vivo. |
![Acetamide, 2-chloro-N-[2-(4-methoxyphenyl)-2H-benzotriazol-5-yl]- Structure](/CAS/20210305/GIF/928712-10-1.gif)
